editor
seriou
pulmonari
ill
caus
highli
contagi
novel
coronaviru
sever
acut
respiratori
syndrom
sar
coronaviru
global
pandem
mortal
risk
factor
includ
advanc
age
male
sex
certain
comorbid
includ
immunosuppress
besid
direct
viralinduc
injuri
host
cytokinemedi
antivir
respons
potenti
tissu
damag
pemphigu
mucocutan
autoimmun
blister
diseas
increas
infect
risk
via
multipl
mechan
includ
epitheli
barrier
breakdown
therapyrel
immunosuppress
given
need
balanc
appropri
pemphigu
treatment
reduct
mortal
risk
outlin
treatment
consider
particularli
vulner
patient
popul
rituximab
chimer
monoclon
antibodi
unit
state
food
drug
administr
fda
approv
medic
moder
sever
pemphigu
consid
firstlin
therapi
base
welldocu
efficaci
safeti
profil
howev
effect
bcell
irrevers
reconstitut
bcell
immun
take
month
could
problemat
patient
contract
addit
logist
intraven
infus
may
feasibl
limit
nonemerg
medic
care
mandat
taken
approach
postpon
rituximab
infus
temporarili
aim
delay
peak
patient
immunosuppress
peak
incid
reduc
risk
advers
outcom
besid
rituximab
mainstay
pemphigu
treatment
glucocorticoid
due
rapid
onset
efficaci
low
cost
howev
nonspecif
immunosuppress
effect
increas
infect
risk
among
complic
dosedepend
manner
basic
therapeut
principl
particular
import
pandem
glucocorticoid
steroidspar
immunosuppress
agent
azathioprin
mycophenol
mofetil
taper
lowest
effect
dose
activ
infect
immunosuppress
steroidspar
medic
discontinu
possibl
although
glucocorticoid
cessat
often
consid
due
risk
adren
insuffici
effect
adjuv
treatment
pemphigu
intraven
immunoglobulin
support
immun
therefor
may
use
set
addit
hydroxychloroquin
use
treat
pemphigu
elderli
pregnanc
propos
treatment
although
proof
plasmapheresi
efficaci
mainli
anecdot
pemphigu
could
also
consid
effect
convalesc
plasma
fdaapprov
treatment
activ
investig
pemphigu
unknown
emerg
select
agent
pemphigu
may
offer
certain
pharmacolog
advantag
exampl
new
oral
bruton
tyrosin
kinas
inhibitor
current
phase
clinic
trial
work
via
revers
coval
bind
therefor
selflimit
immunomodulatori
effect
compassion
access
agent
extraordinari
circumst
would
use
addit
ofatumumab
fulli
human
monoclon
antibodi
shorter
act
rituximab
despit
earli
promis
agent
pemphigu
phase
clinic
trial
prematur
termin
due
chang
sponsor
prioriti
tocilizumab
human
monoclon
antibodi
interleukin
propos
treat
inflammatori
phase
report
anecdot
help
pemphigu
suffici
experi
pemphigu
avail
guid
therapeut
decis
make
advoc
thought
pharmacolog
select
well
adher
basic
infectionprevent
principl
social
distanc
hand
wash
reduct
iatrogen
immunosuppress
feasibl
